FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Kauffman Michael					2. Issuer Name and Ticker or Trading Symbol Kezar Life Sciences, Inc. [KZR]								heck a	all applic Directo	cable) or	g Pers	10% Ov	vner	
(Last) (First) (Middle) C/O KEZAR LIFE SCIENCES, INC. 4000 SHORELINE COURT, SUITE 300						3. Date of Earliest Transaction (Month/Day/Year) 01/03/2022									below)	(give title		Other (s below)	specify
(Street) SOUTH SAN FRANCISCO CA 94080				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individ ne) X						
(City)	(St	ate) ((Zip)																
		Tab	le I - No	n-Deriv	/ative	Sec	uriti	ies Ac	quired	, Di	sposed o	f, or Be	neficia	lly C	wned	l			
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day				Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acqu Disposed Of (D) (I				Acquired (A) or (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported		Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code	v	Amount	(A) or (D)	Price	1	Transact (Instr. 3	tion(s)			(111501.4)	
Common Stock 01/03/2			2022	022					5,000	A	\$5.9	1	68,690		D				
Common Stock 01/03/20			2022	022		S ⁽¹⁾		5,000	D	\$16.4	5.45 ⁽²⁾ 63		3,690		D				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) if any		n Date,	4. Transaction Code (Instr. 8)		n of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Deri Sec	rice of ivative curity etr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares	1					
Stock Option (Right to Buy)	\$5.91	01/03/2022			М			5,000	(3)		04/15/2028	Common Stock	5,000	\$	0.00	3,896		D	

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$16.164 to \$16.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 3. Fully vested and exercisable.

Remarks:

/s/ Marc Belsky, Attorney-in-

Fact

01/05/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.